FDA Clears Wandercraft Eve as First Self-Balancing Personal Exoskeleton for Spinal Cord Injury

The clearance rests on an open-label trial at Kessler Foundation and two other sites where participants with spinal cord injury and trained companions learned device operation. Endpoints included walking performance, activities of daily living, and safety on indoor and adjacent outdoor surfaces. No randomized control arm was reported, and the agency emphasized supervised use only.

Participants noted gains in endurance, psychological well-being, and some secondary benefits such as reduced spasticity or improved sleep, yet these were self-reported without blinded assessment or long-term follow-up data. The device requires a remote control and a companion, limiting independence compared with earlier claims about hands-free mobility.

Prior exoskeleton clearances, such as ReWalk and Ekso, were restricted to clinical settings; Eve's home and community labeling marks a regulatory shift. However, the absence of large-scale effectiveness data or cost-effectiveness analysis leaves open questions about real-world adoption and payer coverage.

Next steps include post-market surveillance and studies examining fall rates, cardiovascular outcomes, and quality-of-life metrics over 12 months in broader populations.